Phenylephrine Drugs Market – By Product (Tablets, Syrup, Eye Drops), Route of Administration (Oral, Parenteral), Indication (Cold, Nasal Decongestion, Allergic Reaction), Distribution Channel (Hospital, Retail, & Online) – Global Forecast 2024 – 2032

Phenylephrine Drugs Market Size

Phenylephrine Drugs Market size was valued at USD 21.7 Billion in 2023 growing at a CAGR of 6.6% between 2024 and 2032, driven by factors such as the increase in prevalence of respiratory disease such as the common cold, allergies, and sinusitis. As the prevalence of these conditions rises, the demand for phenylephrine-based drugs also increases.
 

For instance, as per the report published by The Centers for Disease Control and Prevention (CDC) in January 2022, it has been reported that around 28.9 million adults in the U.S. were diagnosed with sinusitis, and the percentage of adults with diagnosed sinusitis were 11.6%. Thus, the rise in the prevalence of respiratory disease increases the number of visits to physician office, that increases the demand for phenylephrine.
 

Moreover, the increase in preference for non-sedating decongestant propel the growth of the market, as phenylephrine is favoured over pseudoephedrine, another decongestant, in many over-the-counter cold and allergy medications due to its non-sedating properties. As consumers increasingly seek medications that do not cause drowsiness, the demand for phenylephrine drugs grows.
 

Phenylephrine is used to relieve nasal discomfort caused by colds, allergies, and hay fever. It is also used to relieve sinus congestion and pressure. Phenylephrine relieves symptoms but will not treat the cause of the symptoms or speed recovery. Phenylephrine is in a class of medications called nasal decongestants. It works by reducing swelling of the blood vessels in the nasal passages. It primarily acts as an alpha-1 adrenergic receptor agonist and exhibits minimal to no beta-adrenergic activity.
 

Phenylephrine Drugs Market Trends

• With a rise in respiratory illnesses like the common cold, allergies, sinusitis, and influenza, there's a corresponding increase in symptoms such as nasal congestion, sinus pressure, and runny nose. These discomforts drive individuals to seek relief, often turning to medications for symptomatic management that propels the growth of the market. For instance, as per the report published by Asthma and Allergy Foundation of America, in March 2023, more than 100 million people in the U.S. experience various types of allergies each year. Allergies are the sixth leading cause of chronic illness in the U.S. Each year in the U.S., it is estimated that anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits.
   
• Furthermore, the prevalence of these respiratory ailments leads to a greater preference for over the counter (OTC) drugs. Phenylephrine-based products, readily available without a prescription, capitalize on this trend, offering consumers quick access to relief.
   

Phenylephrine Drugs Market Analysis

Based on the product type, the market is classified into tablets, syrups, eye drops and other product types. The tablets segment dominated the market with revenue of USD 8.1 billion in 2023.
 

• Phenylephrine tablets are widely available as over the counter (OTC) products, allowing consumers to purchase them without a prescription. The accessibility and convenience of OTC phenylephrine tablets drive consumer demand and market growth.
   
• Moreover, regulatory approvals and guidelines supporting the safety and efficacy of phenylephrine tablets contribute to market growth by boosting consumer confidence and facilitating product sales. Compliance with regulatory requirements ensures the quality and integrity of phenylephrine tablets, enhancing their market acceptance.
   
• In addition, the increasing awareness about the risks associated with pseudoephedrine and the availability of non-sedating alternatives like phenylephrine tablets, there is a growing consumer preference for phenylephrine-based products that propel the growth of the market.

Based on the route of administration, the phenylephrine drugs market is classified into oral, parenteral, other routes of administration. The oral segment dominated the market with market share of 52.5% in 2023.
 

• The rising consumer preference for oral dosage form due to their ease of administration and convenience. Oral phenylephrine drugs, such as tablets and liquid formulations, offer a simple and familiar route of administration, making them preferred choices for individuals seeking relief from nasal congestion and related symptoms.
   
• Moreover, the oral route of administration is non-invasive, making it suitable for individuals who may prefer to avoid injections or nasal spray. Oral phenylephrine drugs can be taken orally with water or other liquids, eliminating the need for additional devices or equipment for administration.
   

Based on indication, the phenylephrine drugs market is classified into cold, nasal decongestion, allergic reaction, eye disease, and other indications. Cold segment is expected to exhibit 7% CAGR between 2024 - 2032.
 

• The rise in the prevalence of the common cold affecting millions of individuals worldwide each year increases the demand for drugs such as phenylephrine to treat infectious diseases propel the growth of the market.
   
• Moreover, cold symptoms are more prevalent during certain seasons, such as fall and winter, when cold viruses are more active. During these times, there is typically an increased demand for cold medications, including those containing phenylephrine, to manage symptoms and provide relief to affected individuals.
   

Based on distribution channel, the phenylephrine drugs market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Drug stores & retail pharmacies segment is expected to exhibit 6.9% CAGR between 2024 - 2032.
 

• Drug stores and retail pharmacies offer convenient access to a wide range of medications, including phenylephrine-based products, in easily accessible locations. Consumers can purchase these medications without the need for a prescription, making it convenient for them to obtain relief from nasal congestion and related symptoms.
   
• Moreover, with the growing trend toward self-medication and self-care, consumers are more inclined to purchase over-the-counter medications directly from drug stores and retail pharmacies. Phenylephrine-based products cater to this trend by offering effective relief from nasal congestion without the need for a prescription. 

In 2023, North America secured a substantial market share of 39.7% in the global phenylephrine drugs market and is expected to dominate throughout the forecast period.
 

• North America experiences a significant burden of respiratory conditions such as the common cold, allergies, sinusitis, and influenza. These conditions often result in nasal congestion and related symptoms, driving the demand for phenylephrine drugs as decongestants.
   
• Regulatory restrictions on pseudoephedrine, which can be misused in the illicit production of methamphetamine, have led to increased use of phenylephrine as an alternative decongestant in North America. These regulatory constraints drive market growth by expanding the market share of phenylephrine drugs.
  
   

The phenylephrine drugs market in U.S. is expected to exhibit 6.9% CAGR between 2024 - 2032.
 

• The U.S. government regulates the sale of pseudoephedrine due to its potential use in illicit drug manufacturing. This has led to the popularity of phenylephrine as an alternative decongestant, driving the growth of phenylephrine drugs in the market.
   
• Moreover, the rise in the prevalence of seasonal allergies and respiratory illness in U.S. such as hay fever and the flu. These conditions drive the demand for phenylephrine drugs, as they are commonly used to treat symptoms like nasal congestion.

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

• The upsurge in technological advancement has played a major role in driving the growth of the market. In addition, the advances in drug formulations and delivery systems may influence the growth of the phenylephrine drugs market in Germany. Innovative products offering improved efficacy or convenience, such as extended-release formulations or combination drugs, can attract consumers and contribute to market expansion.

The India phenylephrine drugs market is expected to grow with a significant CAGR during the forecast period.
 

• The high prevalence of respiratory disease in India, including common colds, flu, and allergies, particularly during certain seasons. Nasal congestion is a common symptom of these illnesses, driving the demand for phenylephrine drugs to alleviate congestion and related discomfort.
   
• Moreover, rapid urbanization and changing lifestyles in India have led to increased exposure to pollution, allergens, and other environmental factors that can trigger respiratory problems. As more people move to urban areas and adopt sedentary lifestyles, the demand for medications to manage respiratory symptoms, including phenylephrine drugs, is expected to rise.
   

Brazil secured a substantial market share in the global phenylephrine drugs market.
 

• Brazil's tropical climate contributes to environmental factors such as high humidity and pollen levels, which can exacerbate respiratory issues and nasal congestion. The prevalence of these environmental factors drives the demand for medications like phenylephrine that provide relief from congestion.
   
• Moreover, pharmaceutical companies in Brazil invest in advertising and marketing campaigns to promote over-the-counter medications, including those containing phenylephrine. These efforts increase awareness and drive consumer demand for phenylephrine products.
   

Phenylephrine Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that involved in the production of phenylephrine-based drugs to treat allergic disorders vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for phenylephrine drugs.
 

Phenylephrine Drugs Market Companies

Prominent players operating in the phenylephrine drugs industry are as mentioned below:

• Novartis AG
• Perrigo Company PLC
• Johnson & Johnson Consumer Inc. (Kenvue Inc.)
• Proctor & Gamble Co.
• Pfizer, Inc.
• Foundation Consumer Brands LLC
• Mylan N.V.
• Torrent Pharmaceuticals, Inc.
• GlaxoSmithKline PLC
• Bayer AG
   

Phenylephrine Drugs Industry News

• In December 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, launched phenylephrine hydrochloride injection, USP, in 500mcg/5mL and 1,000mcg/10mL doses. The product has been launched in the U.S. in ready-to-use vials. It is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anaesthesia.
   
• In October 2019, Eton Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced that the U.S. Food and Drug Administration (FDA) has approved Biorphen, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anaesthesia.
   

The phenylephrine drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Tablets
• Syrups
• Eye drops
• Other product types

Market, By Route of Administration

• Oral
• Parenteral
• Other routes of administration

Market, By Indication

• Cold
• Nasal decongestion
• Allergic reaction
• Eye disease
• Other indications

Market, By Distribution Channel

• Hospital pharmacies
• Drug stores & retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa